{
    "ticker": "CING",
    "name": "Cingulate, Inc.",
    "description": "Cingulate, Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics for attention-deficit/hyperactivity disorder (ADHD) and related conditions. Founded in 2016, Cingulate focuses on creating next-generation medications that improve treatment outcomes for patients suffering from ADHD and other neurodevelopmental disorders. The company's lead product candidate, CTx-1301, is a novel extended-release formulation of methylphenidate designed to provide a smoother pharmacokinetic profile and better control of ADHD symptoms throughout the day. Cingulate employs its proprietary drug delivery technology to enhance the therapeutic effectiveness while minimizing side effects commonly associated with traditional ADHD treatments. With a strong commitment to research and development, Cingulate aims to address the unmet needs in the ADHD market and improve the quality of life for patients and their families. The company's mission is to advance precision medicine in the treatment of ADHD, leveraging scientific insights to develop tailored therapies that cater to individual patient needs.",
    "industry": [
        "Biopharmaceutical"
    ],
    "headquarters": "Overland Park, Kansas, USA",
    "founded": "2016",
    "website": "https://www.cingulate.com",
    "ceo": "Shaun Thaxter",
    "social_media": {
        "twitter": "https://twitter.com/CingulateInc",
        "linkedin": "https://www.linkedin.com/company/cingulate/"
    },
    "investor_relations": "https://www.cingulate.com/investors",
    "key_executives": [
        {
            "name": "Shaun Thaxter",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael T. O'Rourke",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "ADHD Treatments",
            "products": [
                "CTx-1301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cingulate, Inc. | Innovative ADHD Therapeutics",
        "meta_description": "Learn about Cingulate, Inc., a biopharmaceutical company focused on developing advanced treatments for ADHD. Explore our innovative approaches and product pipeline.",
        "keywords": [
            "Cingulate",
            "ADHD",
            "Biopharmaceutical",
            "CTx-1301",
            "Attention-Deficit/Hyperactivity Disorder",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Cingulate focus on?",
            "answer": "Cingulate focuses on developing innovative therapeutics for ADHD and related conditions."
        },
        {
            "question": "What is CTx-1301?",
            "answer": "CTx-1301 is Cingulate's lead product candidate, a novel extended-release formulation of methylphenidate for ADHD treatment."
        },
        {
            "question": "When was Cingulate founded?",
            "answer": "Cingulate was founded in 2016."
        },
        {
            "question": "Where is Cingulate headquartered?",
            "answer": "Cingulate is headquartered in Overland Park, Kansas, USA."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "SHYF",
        "AVLR"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "VRTX"
    ]
}